Announcements Trials
Browse Landscape

Phase

Phase 2 35Phase 1 9Phase 3 2Phase 1/2 2

Status

Unknown 1Completed 1

Sponsor Class

OTHER 19INDUSTRY 8NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Breast Neoplasms 1

Interventions

Cyclophosphamide 44Biopsy 35Specimen Handling 34Magnetic Resonance Spectroscopy 30fludarabine 27aldesleukin 26Filgrastim 20Carboplatin 20Paclitaxel 19fludarabine phosphate 17Rituximab 17Sirolimus 16Cisplatin 16Temozolomide 15Radiotherapy 14Etoposide 14Bevacizumab 14Prednisone 13Gemcitabine 13Docetaxel 13Cytarabine 13Erlotinib Hydrochloride 12Fluorouracil 11Vorinostat 10Vincristine 10Sorafenib 10Electrocardiography 10Doxorubicin 10temsirolimus 9pembrolizumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × NIH × Sunitinib × Clear all
NCT00453154 2023-04-04

Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
156 enrolled 14 charts
Thoracic

Small Cell Lung Carcinoma

NCT00931450 2013-08-12

Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer

National Cancer Institute (NCI)

Phase 1/2 Unknown
70 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡